He Kuifeng, Cui Binbin, Li Guangliang, Wang Haohao, Jin Ketao, Teng Lisong
Department of Surgical Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Onco Targets Ther. 2012;5:59-65. doi: 10.2147/OTT.S29719. Epub 2012 Apr 13.
Significant progression has been achieved in the treatment of metastatic colorectal cancer (mCRC) in recent years. This has been partly attributed to successfully incorporating new drugs into combination chemotherapy. In addition to the traditional cytotoxic chemotherapeutic agents, molecularly targeted agents began to play an important role in the treatment of advanced solid tumors. To date, two classes of molecularly targeted agents have been approved for treatment of patients with mCRC: (1) antivascular endothelial growth factor (anti-VEGF) agents (such as bevacizumab and aflibercept) and (2) antiendothelial cell growth factor receptor (anti-EGFR) agents (such as cetuximab and panitumumab). Aflibercept is a new member of anti-VEGF agents which has demonstrated efficacy for treatment of mCRC. With the commencement of clinical trials and basic research into aflibercept, more data from the bedside and the bench have been obtained. This review will outline the application of anti-VEGF agents by reviewing clinic experiences of bevacizumab and aflibercept, and try to add perspectives on the use of anti-VEGF agents in mCRC.
近年来，转移性结直肠癌（mCRC）的治疗取得了显著进展。这部分归功于成功地将新药纳入联合化疗。除了传统的细胞毒性化疗药物外，分子靶向药物开始在晚期实体瘤的治疗中发挥重要作用。迄今为止，已有两类分子靶向药物被批准用于治疗mCRC患者：（1）抗血管内皮生长因子（anti-VEGF）药物（如贝伐单抗和阿柏西普）和（2）抗内皮细胞生长因子受体（anti-EGFR）药物（如西妥昔单抗和帕尼单抗）。阿柏西普是抗VEGF药物的新成员，已证明对mCRC治疗有效。随着阿柏西普临床试验和基础研究的开展，已获得了更多来自临床和实验室的数据。本综述将通过回顾贝伐单抗和阿柏西普的临床经验概述抗VEGF药物的应用，并尝试对mCRC中抗VEGF药物的使用增加一些观点。
